DUBLIN–(BUSINESS WIRE)–July 8, 2022–

The “Global Bioprosthetic Heart Valve Market 2022-2028” report has been added to ResearchAndMarkets.com’s offering.

The global bioprosthetic heart valve market is expected to grow at a substantial CAGR of 11.4% during the forecast period. Continuous improvements and development in healthcare facilities are supporting the implantation of the bioprosthetic heart valve in developing countries, which in turn is driving the growth of the market over the forecast period.

For example, the most recent development in bioprosthetic heart valve technology is percutaneous (or transcatheter) valve replacement, which involves replacement of the aortic valve in a minimally invasive procedure with catheterization from a large blood vessel, the more often the femoral artery. However, the high cost of these procedures, along with the lack of skilled professionals, is hampering the growth of the market. Additionally, strict government regulations on product approvals have hampered the growth of the market.

The global bioprosthetic heart valve market is segmented on the basis of type and end-user. Based on type, the market is segmented into homograft, heterograft, bovine pericardial valve and stentless valves. On the basis of end user, the market is sub-segmented into hospitals, research institutes and others. On the basis of end-user, the hospital segment is expected to exhibit the fastest growth in the global bioprosthetic heart valve market during the forecast period. The growth attributed to the availability of various surgical procedures in such settings.

For example, in 2021, CARMAT announced the first implantation of its Aeson bioprosthetic artificial heart in a commercial setting. This implant of the Aeson artificial heart was performed at the Azienda Ospedalieradei Colli Hospital in Naples. 5 German hospitals have already been trained by CARMAT and are currently screening patients for an implant.

Geographically, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. Asia-Pacific is expected to be the fastest growing region due to increasing geriatric population and increasing incidence and prevalence rate of heart disease. According to the American College of Cardiology Foundation, more than half of all CVD deaths worldwide in 2019 occurred in Asian countries and from 1990 to 2019, the number of CVD deaths in Asia increased from 5.6 million to 10.8 million.

Major companies serving the global bioprosthetic heart valve market include Medtronic International Trading Sarl, TTK Healthcare Ltd., Edwards Lifesciences Corp., Boston Scientific Corp., Abbott Laboratories, and others.

Market players are significantly contributing to the growth of the market by adopting various strategies including mergers and acquisitions, partnerships, collaborations, financing, and new product launches to stay competitive in the market. For example, in 2021, St. Jude Medical, Inc., a global medical device company, announced regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) and launch of the Trifecta aortic stent pericardial tissue. The first procedures were performed at Osaka University Hospital and Saitama Medical University International Medical Center in Japan.

The report covers

  • Comprehensive research methodology of the global Bioprosthetic Heart Valves Market.
  • This report also includes a detailed and comprehensive overview of the market with key insights from analysts.
  • A comprehensive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global Bioprosthetic Heart Valves market.
  • Overview of market determinants driving the global bioprosthetic heart valves market.
  • Detailed and extensive market segments with the regional breakdown of forecast revenue.
  • Detailed profiles and recent developments of market players.

Main topics covered:

1. Summary of the report

2. Overview and Market Overview

2.1. Report scope

2.2. Analyst overview and current market trends

2.2.1. Main conclusions

2.2.2. Recommendations

2.2.3. Conclusion

3. Competitive Landscape

3.1. Key business analysis

3.1.1. Insight

3.1.2. Financial analysis

3.1.3. SWOT analysis

3.1.4. RECENT DEVELOPMENTS

3.2. Key strategic analysis

3.3. Impact of Covid-19 on key players

4. Market segmentation

4.1. Global Bioprosthetic Heart Valve Market by Type

4.1.1. homograft

4.1.2. Heterograft

4.1.3. Bovine pericardial valve

4.1.4. Stentless Valves

4.2. Global Bioprosthetic Heart Valve Market by End User

4.2.1. Hospitals

4.2.2. Research institutes

4.2.3. Other

5. Regional analysis

5.1. North America

5.1.1. United States

5.1.2. Canada

5.2. Europe

5.2.1. UK

5.2.2. Germany

5.2.3. Italy

5.2.4. Spain

5.2.5. France

5.2.6. The rest of Europe

5.3. Asia Pacific

5.3.1. China

5.3.2. India

5.3.3. Japan

5.3.4. South Korea

5.3.5. Rest of Asia-Pacific

5.4. Rest of the world

6. Company Profiles

6.1. Abbott Laboratories

6.2. Boston Scientific Corp.

6.3. BraileBiomedica

6.4. Colibri LLC Heart Valve

6.5. Edwards Lifesciences Corp.

6.6. enVeno Medical

6.7. Jenavalve Technology Gmbh

6.8. LivaNova PLC

6.9. Medtronic International Trading Sarl

6.10. TTK Healthcare Ltd.

6.11. Symetis SA

6.12. Cryolife Inc.

6.13. Lepu Medical Technology Co.Ltd.

6.14. Foldax, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/69629v

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220708005417/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Officer

[email protected]

For EST business hours, call 1-917-300-0470

For US/CAN call toll free 1-800-526-8630

For GMT office hours call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTHCARE CARDIOLOGY

SOURCE: Research and Markets

Copyright BusinessWire 2022.

PUBLISHED: 07/08/2022 11:44 AM / DISK: 07/08/2022 11:44 AM

http://www.businesswire.com/news/home/20220708005417/en

Recent stories you might have missed